
The Pfizer study was stopped early for efficacy and the company plans to submit data to the US FDA for Emergency Use Authorization as soon as possible, according to a statement.

The Pfizer study was stopped early for efficacy and the company plans to submit data to the US FDA for Emergency Use Authorization as soon as possible, according to a statement.

Semaglutide 2.4 mg led to clinically significant weight loss and improvements in cardiometabolic risk factors in adults with moderate or severe obesity, suggests new research from ObesityWeek 2021.
The evidence that obesity is pathophysiologic dysfunction in the human body places it squarely in the realm of chronic disease, according to obesity specialist Kaplan. Let’s treat it accordingly.
Primary care leadership is essential to the future of obesity medicine, says Kaplan, but treatment needs to be within the normal scope of primary care practice. Hear him explain.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Recognizing obesity as chronic pathophysiologic dysfunction and explaining that to a patient will make them remarkably more receptive to all other discussions about treatment, says obesity specialist Kaplan.

ObesityWeek 2021. Weight loss with semaglutide was more than 2 times greater than with liraglutide in the 68-week placebo-controlled trial of the 2 GLP-1 RAs.

CDC Director Rochelle Walensky officially endorsed Pfizer's COVID-19 vaccine in children aged 5 to 11 years, following recommendation from ACIP.

Data from the CDC on the Delta variant and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

ObesityWeek 2021: Regular engagement in online behavioral obesity treatment program within primary care network produced clinically significant weight loss in new study.
A clinical psychologist from the Mayo Clinic Bariatric Center in Jacksonville, FL, explains and corrects key misperceptions that inhibit open discussion of the therapy.
Alexis Beatty, MD, MAS, highlights findings from the first peer-reviewed published study to report long-term experience with a digital health app for hypertension.

ObesityWeek 2021: New study highlights protective effects of medical weight management during COVID-19 pandemic.

Global confirmed deaths due to COVID-19 have surpassed 5 million. We summarize more of today's data from the Johns Hopkins COVID-19 interactive map and the CDC.

ObesityWeek 2021. Liraglutide helped patients who regained weight after successful gastric bypass surgery re-achieve their lowest weight with an acceptable safety profile.

A rash presumed to be a possible fungal or bacterial infection on the legs and feet of a 62-year-old man has failed to improve after 10 days of treatment. What's your Dx?

ObesityWeek 2021: Weight loss support delivered via pandemic-driven telehealth resulted in clinically significant weight loss, report 2 different research teams.

COVID-19 has changed many of what we know as standard operating procedures during flu season. How would you handle these 5 situations, for example?

Primary nonadherence with anticoagulant therapy may be influenced by which DOAC is prescribed, age, and diagnosis of several chronic diseases, a new study found.

This flu season will bring different challenges to primary care clinicians. Here, experts discuss specific barriers and best strategies to overcome them.